NCT00395421

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

A Partially-blinded, Randomized, Parallel-group Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between Valopicitabine and Ribavirin When Administered in Combination With Pegylated Interferon Alfa-2a in Treatment-naive Patients With Chronic Hepatitis C

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: —

Summary

This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	NM283 plus Peg-IFNα-2a	200 mg QD 180 µg QW

Timeline

• Start date: 2006-10-01
• Primary completion: 2008-06-01
• Completion: 2008-08-01
• First posted: 2006-11-02
• Last updated: 2010-06-10

Locations

2 sites across 1 country: United States